Liver Disease in the Face of COVID-19 and CMV, Inflammation, Morbidity and Mortality in Treated HIV - Jun 23 2021 @ 7:00 PM
Liver Disease in the Face of COVID-19
Elizabeth C. Verna, MD, MSc
Frank Cardile Associate Professor of Medicine, Columbia University Medical Center
Director of Clinical Research, Columbia University Transplant Initiative
and the Transplant Clinical Research Center, New York, NY
Does COVID-19 infection contribute to liver disease? And does pre-existing liver disease affect the course of COVID-19 outcomes? In this presentation, Elizabeth Verna addresses these important questions and also explains how the COVID-19 pandemic has impacted the care of patients with chronic liver disease including the initiatives regarding viral hepatitis elimination.
Inflammation, Morbidity and Mortality in Treated HIV: Roles of Asymptomatic CMV and Sex Differences
Peter W. Hunt, MD
Professor of Medicine, Division of Experimental Medicine, UCSF
Co-Director of Basic/Translational Sciences, Center for AIDS Research
San Francisco, CA
Chronic inflammation caused by herpesviruses (especially CMV) and by sex differences, leads to end-organ morbidities in HIV disease despite optimal treatment of HIV. In this presentation, Peter Hunt explores the causes and consequences of persistent immune activation in treated HIV infection, including its impact on age-related morbidity and mortality as well as HIV persistence.